Literature DB >> 3297732

The effect of chronic captopril therapy on adrenergic receptors, plasma noradrenaline and the vascular responses to infused noradrenaline.

G B Kondowe, S Copeland, A P Passmore, W J Leahey, G D Johnston.   

Abstract

Adrenergic receptors (alpha 2, beta 2), plasma noradrenaline, heart rate and the pressor responsiveness to infused noradrenaline were examined in ten healthy male volunteers before and after 2 weeks of placebo or captopril therapy in a double blind cross-over study. No significant differences in these measurements were observed between the captopril and placebo treated groups. The study shows that in sodium replete normotensive subjects, long-term angiotensin converting enzyme inhibition does not lead to changes in adrenoceptor density. There is also no alteration in plasma noradrenaline levels nor in the pressor responsiveness to infused noradrenaline. These data suggest that the known interaction between the renin-angiotensin system and the sympathetic nervous system observed in animals is probably of little significance in man.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3297732     DOI: 10.1007/BF00607568

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  23 in total

Review 1.  Actions of angiotensin on adrenergic nerve endings.

Authors:  B G Zimmerman
Journal:  Fed Proc       Date:  1978-02

2.  Use of plasma norepinephrine for evaluation of sympathetic neuronal function in man.

Authors:  C R Lake; M G Ziegler; I J Kopin
Journal:  Life Sci       Date:  1976-06-01       Impact factor: 5.037

3.  Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects.

Authors:  E Haber; T Koerner; L B Page; B Kliman; A Purnode
Journal:  J Clin Endocrinol Metab       Date:  1969-10       Impact factor: 5.958

4.  Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

5.  Endocrine profile in the long-term phase of converting-enzyme inhibition.

Authors:  S L Swartz; G H Williams; N K Hollenberg; F R Crantz; T J Moore; L Levine; A A Sasahara; R G Dluhy
Journal:  Clin Pharmacol Ther       Date:  1980-10       Impact factor: 6.875

6.  Attenuation of pressor responses to norepinephrine and pitressin and potentiation of pressor response to angiotensin II by captopril in human subjects.

Authors:  Y Imai; K Abe; M Seino; T Haruyama; J Tajima; M Sato; T Goto; M Hiwatari; Y Kasai; K Yoshinaga; H Sekino
Journal:  Hypertension       Date:  1982 May-Jun       Impact factor: 10.190

7.  Angiotensin-converting enzyme inhibition, catecholamines and hemodynamics in essential hypertension.

Authors:  G Muiesan; C L Alicandri; E Agabiti-Rosei; R Fariello; M Beschi; E Boni; M Castellano; E Moniti; L Muiesan; G Romanelli; A Zanielli
Journal:  Am J Cardiol       Date:  1982-04-21       Impact factor: 2.778

Review 8.  An overview of the clinical pharmacology of enalapril.

Authors:  R O Davies; H J Gomez; J D Irvin; J F Walker
Journal:  Br J Clin Pharmacol       Date:  1984       Impact factor: 4.335

9.  Augmented sympathetic nerve activity and pressor responsiveness in DOCA hypertensive rats.

Authors:  K Takeda; R D Buñag
Journal:  Hypertension       Date:  1980 Jan-Feb       Impact factor: 10.190

10.  Regulation of human leukocyte beta receptors by endogenous catecholamines: relationship of leukocyte beta receptor density to the cardiac sensitivity to isoproterenol.

Authors:  J Fraser; J Nadeau; D Robertson; A J Wood
Journal:  J Clin Invest       Date:  1981-06       Impact factor: 14.808

View more
  2 in total

Review 1.  ACE inhibitors. Drug interactions of clinical significance.

Authors:  C Mignat; T Unger
Journal:  Drug Saf       Date:  1995-05       Impact factor: 5.606

2.  Interactions between cilazapril and propranolol in man; plasma drug concentrations, hormone and enzyme responses, haemodynamics, agonist dose-effect curves and baroreceptor reflex.

Authors:  G G Belz; J Essig; C H Kleinbloesem; J F Hoogkamer; U W Wiegand; A Wellstein
Journal:  Br J Clin Pharmacol       Date:  1988-11       Impact factor: 4.335

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.